ANRO
Alto Neuroscience, Inc.
NYSE: ANRO · HEALTHCARE · BIOTECHNOLOGY
$25.80
+6.15% today
Updated 2026-04-30
Market cap
$859.49M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.19
Dividend yield
—
52W range
$2 – $28
Volume
0.3M
Alto Neuroscience, Inc. (ANRO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $-9.26M | $-20.39M | $-33.45M | $-47.42M | $-51.77M |
| Capital expenditures | $680000.00 | $732000.00 | $470000.00 | $2.08M | $24000.00 |
| Depreciation | — | — | — | — | — |
| Stock-based comp | $227000.00 | $1.76M | $2.89M | $7.63M | $8.11M |
| Free cash flow | $-9.94M | $-21.13M | $-33.92M | $-49.50M | $-51.79M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt repayment | — | — | — | — | — |
| Net change in cash | — | — | — | — | — |